Risk of Premature Atherosclerotic Disease in Patients W Familial Hypercholesterolemia

Journal of the American College of Cardiology

74, 512-522

DOI: 10.1016/j.jacc.2019.05.043

Citation Report

#	Article	IF	Citations
1	Polygenic Risk Scores in FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2019, 74, 523-525.	1.2	6
2	Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Progress in Cardiovascular Diseases, 2019, 62, 414-422.	1.6	34
3	Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders. Nature Communications, 2019, 10, 4897.	5.8	89
4	Familial Hypercholesterolaemia in 2020: AÂLeading Tier 1 Genomic Application. Heart Lung and Circulation, 2020, 29, 619-633.	0.2	22
5	Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?. Clinical Genetics, 2020, 97, 543-555.	1.0	6
6	Can genetic testing help in the management of dyslipidaemias?. Current Opinion in Lipidology, 2020, 31, 187-193.	1.2	9
7	The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women. Current Atherosclerosis Reports, 2020, 22, 46.	2.0	14
8	PCSK9 Gene E670G Polymorphism and Coronary Artery Disease: An Updated Meta-Analysis of 5,484 Subjects. Frontiers in Cardiovascular Medicine, 2020, 7, 582865.	1.1	12
9	Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor. Frontiers in Genetics, 2020, 11, 554931.	1.1	5
10	Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia. Clinical Genetics, 2020, 98, 457-467.	1.0	13
11	Next-generation sequencing to confirm clinical familial hypercholesterolemia. European Journal of Preventive Cardiology, 2020, , 204748732094299.	0.8	12
12	Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. Circulation Genomic and Precision Medicine, 2020, 13, 515-523.	1.6	36
13	Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1Î± and activating FoxO3a. Journal of Translational Medicine, 2020, 18, 195.	1.8	22
14	Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 2682-2693.	1.2	50
15	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease. Circulation, 2020, 141, 1742-1759.	1.6	301
16	The brave new world of genetic testing in the management of the dyslipidaemias. Current Opinion in Cardiology, 2020, 35, 226-233.	0.8	10
17	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. Atherosclerosis, 2020, 298, 52-57.	0.4	14
18	Editor-in-Chiefâ€™s Top Picks From 2019. Journal of the American College of Cardiology, 2020, 75, 776-834.	1.2	0

#	Article	IF	Citations
19	Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2020, 5, 390.	3.0	146
20	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nature Reviews Cardiology, 2020, 17, 360-377.	6.1	82
21	Editorial Commentary: What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?. Trends in Cardiovascular Medicine, 2021, 31, 216-217.	2.3	0
22	Familial hypercholesterolemia and cardiovascular disease in older individuals. Atherosclerosis, 2021, 318, 32-37.	0.4	12
23	Structural and Molecular Interaction Studies on Familial Hypercholesterolemia Causative PCSK9 Functional Domain Mutations Reveals Binding Affinity Alterations with LDLR. International Journal of Peptide Research and Therapeutics, 2021, 27, 719-733.	0.9	6
24	Past, Present, and Future of Familial Hypercholesterolemia Management. Methodist DeBakey Cardiovascular Journal, 2021, 17, 28-35.	0.5	9
26	The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case. Current Opinion in Lipidology, 2021, 32, 89-95.	1.2	10
27	Improving Familial Hypercholesterolemia Index Case Detection: Sequential Active Screening from Centralized Analytical Data. Journal of Clinical Medicine, 2021, 10, 749.	1.0	6
28	The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives. Current Opinion in Lipidology, 2021, 32, 112-116.	1.2	16
29	Polygenic Risk Score for Low-Density Lipoprotein Cholesterol Is Associated With Risk of Ischemic Heart Disease and Enriches for Individuals With Familial Hypercholesterolemia. Circulation Genomic and Precision Medicine, 2021, 14, e003106.	1.6	21
30	Molecular Genetic Approach and Evaluation of Cardiovascular Events in Patients with Clinical Familial Hypercholesterolemia Phenotype from Romania. Journal of Clinical Medicine, 2021, 10, 1399.	1.0	3
31	Polygenic risk scores: how much do they add?. Current Opinion in Lipidology, 2021, 32, 157-162.	1.2	10
32	Genetics of Cardiovascular Disease: How Far Are We from Personalized CVD Risk Prediction and Management?. International Journal of Molecular Sciences, 2021, 22, 4182.	1.8	25
33	Genetic basis of hypercholesterolemia in adults. Npj Genomic Medicine, 2021, 6, 28.	1.7	22
34	Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia. Journal of Human Genetics, 2021, 66, 1079-1087.	1.1	9
35	The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. Journal of Personalized Medicine, 2021, 11, 464.	1.1	14
36	Use of commercial genetic testing to help reclassify LDL receptor variants in clinical practice: A case report. Journal of Clinical Lipidology, 2021, 15, 447-450.	0.6	0
37	Patient Perspectives Regarding Genetic Testing for Familial Hypercholesterolemia. CJC Open, 2021, 3, 557-564.	0.7	6

#	Article	IF	Citations
38	Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. Nature Communications, 2021, 12, 3505.	5.8	49
39	Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands. Genes, 2021, 12, 1168.	1.0	12
40	Variable and Severe Phenotypic Expression of the â€œLebanese Alleleâ€•in Two Sisters with Familial Hypercholesterolemia. Vascular Health and Risk Management, 2021, Volume 17, 415-419.	1.0	2
41	Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia. Expert Review of Molecular Diagnostics, 2021, 21, 887-895.	1.5	8
42	Familial Hypercholesterolemia, Familial Combined Hyperlipidemia and Elevated Lipoprotein(a) in Patients with Premature Coronary Artery Disease. Canadian Journal of Cardiology, 2021, 37, 1733-1742.	0.8	7
43	Hypercholesterolemia at a young age. , 2021, 17, 83-93.	0.0	0
44	Cutaneous manifestations in familial hypercholesterolaemia. Atherosclerosis, 2021, 333, 116-123.	0.4	9
45	AtualizaÃ§Ã£o da Diretriz Brasileira de Hipercolesterolemia Familiar â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 782-844.	0.3	10
46	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2632-2640.	1.1	42
47	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2020, 14, 398-413.	0.6	70
48	Next-generation sequencing to confirm clinical familial hypercholesterolemia. European Journal of Preventive Cardiology, 2021, 28, 875-883.	0.8	23
49	Familial hypercholesterolemia. Current Opinion in Lipidology, 2020, 31, 111-118.	1.2	11
50	Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance. Current Opinion in Lipidology, 2021, 32, 103-111.	1.2	11
52	Appropriate Use Criteria for PET Myocardial Perfusion Imaging. Journal of Nuclear Medicine, 2020, 61, 1221-1265.	2.8	36
53	The utility of MLPA in Familial Hypercholesterolemia diagnosis. Acta Marisiensis - Seria Medica, 2021, 67, 162-166.	0.2	0
54	Familial hypercholesterolemia: case series of a rare condition. Russian Journal of Cardiology, 2021, 26, 4610.	0.4	1
55	Genetic testing for familial hypercholesterolemiaâ€”past, present, and future. Journal of Lipid Research, 2021, 62, 100139.	2.0	20
56	Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia. Atherosclerosis, 2022, 340, 61-67.	0.4	6

#	Article	IF	Citations
57	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approachâ€"Reply. JAMA Cardiology, 2020, 5, 1453.	3.0	0
58	Management of Homozygous Familial Hypercholesterolemia. Contemporary Cardiology, 2021, , 383-404.	0.0	0
59	Prevalence of cardiovascular events in genetically confirmed versus unconfirmed familial hypercholesterolaemia. Global Cardiology Science & Practice, 2020, 2020, e202024.	0.3	1
61	Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 704501.	1.1	5
62	Letter by Tromp et al Regarding Article, â€œLarge-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Icelandâ€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, e44-e45.	1.1	0
64	Polygenic risk scores for cardiovascular disease prediction in the clinical practice: Are we there?. Atherosclerosis, 2022, 340, 46-47.	0.4	4
66	Hematological Inflammatory Markers in Patients with Clinically Confirmed Familial Hypercholesterolemia. BioMed Research International, 2022, 2022, 1-6.	0.9	4
67	Polygenic risk scores for the diagnosis and management of dyslipidemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, Publish Ahead of Print, .	1.2	1
68	Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members. Biomedicines, 2022, 10, 367.	1.4	1
69	The design and rationale of the Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE) study. American Heart Journal Plus, 2022, 13, 100097.	0.3	0
70	Genetic Lipid Disorders Associated with Atherosclerotic Cardiovascular Disease. Medical Clinics of North America, 2022, 106, 325-348.	1.1	3
71	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters. Frontiers in Genetics, 2022, 13, 849008.	1.1	4
72	Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?. Current Atherosclerosis Reports, 2022, 24, 419-426.	2.0	8
73	Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2022, 24, 407-418.	2.0	9
74	Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients. Atherosclerosis, 2022, 347, 63-67.	0.4	5
77	Contribution of rare variants in monogenic diabetes-genes to early-onset type 2 diabetes. Diabetes and Metabolism, 2022, 48, 101353.	1.4	3
79	A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia. Journal of Clinical Lipidology, 2022, 16, 525-529.	0.6	2
80	Subclinical Atherosclerosis Determined by Coronary Artery Calcium Deposition in Patients with Clinical Familial Hypercholesterolemia. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
81	An LDLR missense variant poses high risk of familial hypercholesterolemia in 30% of Greenlanders and offers potential of early cardiovascular disease intervention. Human Genetics and Genomics Advances, 2022, 3, 100118.	1.0	4
82	NANOPARTICLES OF BROWN SEAWEED (SARGASSUM POLYCYSTUM) EXTRACT AND ITS ANTIOXIDANT ACTIVITY IN RATS FED HIGH-FAT DIET. International Journal of Applied Pharmaceutics, 0, , 186-191.	0.3	1
83	Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort. Atherosclerosis Plus, 2022, 49, 47-55.	0.3	1
84	Lipoprotein (a) in familial hypercholesterolaemia. Current Opinion in Lipidology, 2022, Publish Ahead of Print, .	1.2	0
85	Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
86	Novel polymorphism of HMGCR gene related to the risk of diabetes in premature tripleâ€vessel disease patients. Journal of Gene Medicine, 0, , .	1.4	1
87	Evaluation of a novel rapid genomic test including polygenic risk scores for the diagnosis and management of familial hypercholesterolaemia. Global Cardiology Science & Practice, 2021, 2021, .	0.3	0
88	In silico analysis of upstream variants in Brazilian patients with Familial hypercholesterolemia. Gene, 2023, 849, 146908.	1.0	2
89	The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia. Current Cardiology Reports, 2022, 24, 1669-1677.	1.3	5
90	Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2022, 29, 2125-2131.	0.8	8
91	Genetic and molecular architecture of familial hypercholesterolemia. Journal of Internal Medicine, 2023, 293, 144-165.	2.7	22
92	Advances and Applications of Polygenic Scores for Coronary Artery Disease. Annual Review of Medicine, 2023, 74, 141-154.	5.0	9
93	ANGPTL3, ANGPTL4, APOA5, APOB, APOC2, APOC3, LDLR, PCSK9, LPL gene variants and coronary artery disease risk. Russian Journal of Cardiology, 2022, 27, 5232.	0.4	1
94	Genetic testing for familial hypercholesterolaemia: utility beyond diagnosis. European Journal of Preventive Cardiology, 0, , .	0.8	1
95	Subclinical atherosclerosis determined by coronary artery calcium deposition in patients with clinical familial hypercholesterolemia. Atherosclerosis Plus, 2022, , .	0.3	0
96	The risk of various types of cardiovascular diseases in mutation positive familial hypercholesterolemia; a review. Frontiers in Genetics, 0, 13, .	1.1	2
97	Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab. Biomedicines, 2022, 10, 3273.	1.4	0
98	A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. Translational Research, 2023, 255, 119-127.	2.2	4

#	Article	IF	Citations
99	Hematological parameters and early-onset coronary artery disease: a retrospective caseâ€“control study based on 3366 participants. Therapeutic Advances in Chronic Disease, 2023, 14, 204062232211426.	1.1	3
100	Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?. Current Opinion in Lipidology, 2023, 34, 52-58.	1.2	0
101	Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia. Circulation Genomic and Precision Medicine, 2023, 16, .	1.6	2
102	Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review. BMJ Open, 2023, 13, e065551.	0.8	1
106	Polygenic Risk Scores. , 2024, , 62-68.e1.		0
120	Advances in familial hypercholesterolemia. Advances in Clinical Chemistry, 2024, , 167-201.	1.8	0